循环肿瘤细胞在尿路上皮癌中的临床应用:现状与未来  

Clinical use of circulating tumor cells in urothelial carcinoma:current situation and future

作　　者：冯映华 王明帅 李瑞芳 王琦 邢念增 FENG Yinghua;WANG Mingshuai;LI Ruifang;WANG Qi;XING Nianzeng(Department of Epidemiology,School of Public Health,Shanxi Medical University,Taiyuan,030001,China;Department of Urology,Cancer Hospital,Chinese Academy of Medical Sciences;Affiliated Cancer Hospital of Shanxi Medical University;School of Basic Medicine,Shanxi Medical University;Department of Surgery,Peking University First Hospital)

机构地区：[1]山西医科大学公共卫生学院流行病学教研室,太原030001 [2]中国医学科学院肿瘤医院泌尿外科 [3]山西医科大学附属肿瘤医院 [4]山西医科大学基础医学院 [5]北京大学第一医院外科

出　　处：《临床泌尿外科杂志》2025年第1期81-85,共5页Journal of Clinical Urology

基　　金：国家重点研发计划“常见多发病防治研究”重点专项项目(No:2023YFC2507000)。

摘　　要：尿路上皮癌(urothelial carcinoma,UC)是泌尿系统中最常见的恶性肿瘤之一,其中膀胱尿路上皮癌(bladder urothelial carcinoma,BLCA)占多数。由于UC的高复发率,患者需要定期复查,但传统的UC诊断和监测方法如尿液细胞学和影像学检查等存在灵敏度特异度低、费用昂贵等问题,因此,迫切需要一种新型、无创、低成本且准确度高的诊断方法改善现状。循环肿瘤细胞(circulating tumor cells,CTCs)作为无创性的癌症检测工具,近年来备受瞩目,特别是在癌症管理中的潜在应用。本文对CTCs在UC中早期诊断、疗效监测和预后评估等方面进行系统综述,为UC的诊断和治疗带来新的可能性。Urothelial carcinoma(UC)is one of the most common malignant tumors in the urinary system,of which urothelial carcinoma of bladder is the majority.Due to the high recurrence rate of UC,patients need to be reviewed regularly.However,traditional methods of diagnosis and monitoring of UC,such as urine cytology and imaging,have some problems such as low sensitivity and specificity and high cost.Therefore,a new,non-invasive,low-cost and high accuracy diagnostic method is urgently needed to improve the current situation.Circulating tumor cells(CTCs)have attracted much attention in recent years as non-invasive cancer detection tools,especially for their potential applications in cancer management.In this paper,the early diagnosis,efficacy monitoring and prognosis evaluation of CTCs in UC are systematically reviewed,which brings new possibilities for the diagnosis and treatment of UC.

关 键 词：循环肿瘤细胞 尿路上皮癌 早期诊断 疗效监测 预后 

分 类 号：R737.14[医药卫生—肿瘤]